Wan, and K
Clinical Evidence for Visceral Fat Reduction Multiple randomized controlled trials demonstrate Tesamorelins effectiveness for visceral fat reduction
doi: 10.1126/science.8235659
No obvious toxicity was observed in any of the treatment groups, based on the average body weight, and the size and morphology of heart, liver, lung and kidney tissues, which did not differ significantly from that of control mice (Fig
Nevertheless, a retrospective analysis of T2DM treatment in UK showed that the mean time to add a second oral agent in patients with A1c above 7.0, 7.5 and 8.0%, was 2.9, 1.9 and 1.6 years, respectively
Data availability The raw data and code is available from the corresponding author ([email protected]) on reasonable request